AZN•benzinga•
Syneron Bio Announces Strategic Collaboration With AstraZeneca To Develop Potential First-In-Class Macrocyclic Peptides For The Treatment Of Chronic Diseases; AstraZeneca Will Provide Upfront Payments And Potential Near-Term Milestone Payments Totaling $7
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 21, 2025 by benzinga